Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Stock Drops 8 Percent Despite Strong Q3 Revenues

NEW YORK, Oct. 25 (GenomeWeb News) - Shares in Luminex were down 8 percent, or $.88, at $10.06 in mid-afternoon trading even though the company today reported increased revenues for the third quarter.


As GenomeWeb News reported today, Luminex had a 28.7-percent increase in third-quarter revenues from last year's third quarter revenues. The company noted a significant narrowing in losses.


The company noted an increase in R&D investment drove the increase.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.